Fate Therapeutics (FATE) Other Operating Expenses (2023 - 2024)
Fate Therapeutics (FATE) reported Other Operating Expenses of $14.7 million for Q4 2024, up 836.85% quarter-over-quarter from -$2.0 million in Q1 2023.
Fate Therapeutics (FATE) Other Operating Expenses (2023 - 2024) Analysis & Trends
Fate Therapeutics has reported Other Operating Expenses for 2 years, with the latest figure at $14.7 million in Q4 2024.
- For the quarter ending Q4 2024, Other Operating Expenses changed N/A year-over-year to $14.7 million; the trailing twelve-month figure through Sep 2025 stood at $14.7 million (changed N/A YoY), and the FY2024 full-year result was $14.7 million, up 836.85% from the prior year.
- Other Operating Expenses for Q4 2024 stood at $14.7 million, up from -$2.0 million in the prior quarter.
- The five-year high for Other Operating Expenses was $14.7 million in Q4 2024, with the low at -$2.0 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Fate Therapeutics | 250.86 Mn | 250.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 14.74 Mn |
| Mar 31, 2023 | -2.00 Mn |